|
FR901228A
(fr)
|
1943-01-16 |
1945-07-20 |
Deutsche Edelstahlwerke Ag |
Système d'aimant à entrefer annulaire
|
|
US2940972A
(en)
|
1957-06-27 |
1960-06-14 |
Thomae Gmbh Dr K |
Tri-and tetra-substituted pteridine derivatives
|
|
US4666828A
(en)
|
1984-08-15 |
1987-05-19 |
The General Hospital Corporation |
Test for Huntington's disease
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US4801531A
(en)
|
1985-04-17 |
1989-01-31 |
Biotechnology Research Partners, Ltd. |
Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
|
|
US5272057A
(en)
|
1988-10-14 |
1993-12-21 |
Georgetown University |
Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
|
|
US5192659A
(en)
|
1989-08-25 |
1993-03-09 |
Genetype Ag |
Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
|
|
US5710158A
(en)
|
1991-05-10 |
1998-01-20 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
|
GB9125001D0
(en)
|
1991-11-25 |
1992-01-22 |
Ici Plc |
Heterocyclic compounds
|
|
AU661533B2
(en)
|
1992-01-20 |
1995-07-27 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
EP0698015A1
(en)
|
1993-05-14 |
1996-02-28 |
Genentech, Inc. |
Preparation of n-cyanodithioimino-carbonates and 3-mercapto-5-amino-1h-1,2,4-triazole
|
|
US5700823A
(en)
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
|
IL115256A0
(en)
|
1994-11-14 |
1995-12-31 |
Warner Lambert Co |
6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
|
|
US6331555B1
(en)
|
1995-06-01 |
2001-12-18 |
University Of California |
Treatment of platelet derived growth factor related disorders such as cancers
|
|
US6218529B1
(en)
|
1995-07-31 |
2001-04-17 |
Urocor, Inc. |
Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
|
|
EP0923932B1
(en)
|
1996-02-26 |
2011-06-29 |
Eisai R&D Management Co., Ltd. |
Composition containing antitumor agent
|
|
CA2744096C
(en)
|
1996-07-31 |
2013-07-30 |
Laboratory Corporation Of America Holdings |
Biomarkers and targets for diagnosis, prognosis and management of prostate disease
|
|
TW472045B
(en)
|
1996-09-25 |
2002-01-11 |
Astra Ab |
Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
|
|
AU747026B2
(en)
|
1997-05-28 |
2002-05-09 |
Aventis Pharmaceuticals Inc. |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
|
|
US6235740B1
(en)
|
1997-08-25 |
2001-05-22 |
Bristol-Myers Squibb Co. |
Imidazoquinoxaline protein tyrosine kinase inhibitors
|
|
UA71555C2
(en)
|
1997-10-06 |
2004-12-15 |
Zentaris Gmbh |
Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
|
|
WO1999042461A1
(en)
|
1998-02-23 |
1999-08-26 |
Warner-Lambert Company |
Substituted quinoxaline derivatives as interleukin-8 receptor antagonists
|
|
WO2000042026A1
(en)
|
1999-01-15 |
2000-07-20 |
Novo Nordisk A/S |
Non-peptide glp-1 agonists
|
|
AU5214500A
(en)
|
1999-05-05 |
2000-11-21 |
Centre National De La Recherche Scientifique (C.N.R.S.) |
Means for detecting and treating pathologies linked to fgfr3
|
|
US7135311B1
(en)
|
1999-05-05 |
2006-11-14 |
Institut Curie |
Means for detecting and treating pathologies linked to FGFR3
|
|
EA005287B1
(ru)
|
1999-09-15 |
2004-12-30 |
Уорнер-Ламберт Компани |
Птеридиноны в качестве ингибиторов киназ
|
|
DE10013318A1
(de)
|
2000-03-17 |
2001-09-20 |
Merck Patent Gmbh |
Formulierung enthaltend Chinoxalinderivate
|
|
WO2002076985A1
(en)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
|
US20030235628A1
(en)
|
2001-09-19 |
2003-12-25 |
Rajneesh Taneja |
Methods and pharmaceutical formulations for protecting pharmaceutical compounds from acidic environments
|
|
JP4286146B2
(ja)
|
2001-12-18 |
2009-06-24 |
メルク エンド カムパニー インコーポレーテッド |
メタボトロピックグルタミン酸受容体−５のヘテロアリール置換ピラゾール系調節剤
|
|
US20030229067A1
(en)
|
2001-12-20 |
2003-12-11 |
Arlindo Castelhano |
Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
|
|
ES2333702T3
(es)
|
2001-12-24 |
2010-02-26 |
Astrazeneca Ab |
Derivados de quinazolina sustituidos que actuan como unhibidores de cinasas aurora.
|
|
JP2003213463A
(ja)
|
2002-01-17 |
2003-07-30 |
Sumitomo Chem Co Ltd |
金属腐食防止剤および洗浄液
|
|
CA2480800C
(en)
|
2002-04-08 |
2008-09-23 |
Mark T. Bilodeau |
Inhibitors of akt activity
|
|
US7265378B2
(en)
|
2002-07-10 |
2007-09-04 |
E. I. Du Pont De Nemours And Company |
Electronic devices made with electron transport and/or anti-quenching layers
|
|
PA8577501A1
(es)
|
2002-07-25 |
2004-02-07 |
Warner Lambert Co |
Inhibidores de quinasas
|
|
US7825132B2
(en)
|
2002-08-23 |
2010-11-02 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibition of FGFR3 and treatment of multiple myeloma
|
|
CA2500727A1
(en)
|
2002-10-03 |
2004-04-15 |
Targegen, Inc. |
Vasculostatic agents and methods of use thereof
|
|
US20050267222A1
(en)
|
2002-10-22 |
2005-12-01 |
Dainippon Pharmaceutical Co. Ltd. |
Stabilized composition
|
|
AR043059A1
(es)
|
2002-11-12 |
2005-07-13 |
Bayer Pharmaceuticals Corp |
Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos
|
|
US7098332B2
(en)
|
2002-12-20 |
2006-08-29 |
Hoffmann-La Roche Inc. |
5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
|
|
JP2006516561A
(ja)
|
2003-01-17 |
2006-07-06 |
ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー |
細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類
|
|
US20040204450A1
(en)
|
2003-03-28 |
2004-10-14 |
Pfizer Inc |
Quinoline and quinoxaline compounds
|
|
WO2004098494A2
(en)
|
2003-04-30 |
2004-11-18 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
|
EP1628666B1
(en)
|
2003-05-14 |
2015-09-23 |
NeuroGenetic Pharmaceuticals, Inc. |
Compouds and uses thereof in modulating amyloid beta
|
|
ES2316985T3
(es)
|
2003-05-23 |
2009-04-16 |
Aterna Zentaris Gmbh |
Nuevas piridopirazidinas y su uso como moduladores de quinasas.
|
|
DE10323345A1
(de)
|
2003-05-23 |
2004-12-16 |
Zentaris Gmbh |
Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
|
|
WO2005007099A2
(en)
|
2003-07-10 |
2005-01-27 |
Imclone Systems Incorporated |
Pkb inhibitors as anti-tumor agents
|
|
EP1646383A4
(en)
|
2003-07-21 |
2009-03-25 |
Bethesda Pharmaceuticals Inc |
DESIGN AND SYNTHESIS OF OPTIMIZED LIGANDS FOR PPAR
|
|
BRPI0413234A
(pt)
|
2003-08-01 |
2006-10-03 |
Genelabs Tech Inc |
derivados de imidazola bicìclica contra flaviviridae
|
|
ES2293354T3
(es)
|
2003-10-17 |
2008-03-16 |
4 Aza Ip Nv |
Derivados de pteridina sustituidos por heterociclos y su uso en terapia.
|
|
EP1694308A1
(en)
|
2003-10-30 |
2006-08-30 |
Lupin Ltd. |
Stable formulations of ace inhibitors and methods for preparation thereof
|
|
WO2005047244A2
(en)
|
2003-11-07 |
2005-05-26 |
Chiron Corporation |
Inhibition of fgfr3 and treatment of multiple myeloma
|
|
EA009875B1
(ru)
|
2003-11-20 |
2008-04-28 |
Янссен Фармацевтика Н.В. |
6-алкенил и 6-фенилалкил замещенные 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза) полимеразы
|
|
MXPA06005735A
(es)
|
2003-11-24 |
2006-08-17 |
Hoffmann La Roche |
Pirazolil e imidazolil pirimidinas.
|
|
PL1706385T3
(pl)
|
2003-12-23 |
2011-03-31 |
Astex Therapeutics Ltd |
Pochodne pirazolu jako modulatory kinazy białkowej
|
|
US7205316B2
(en)
|
2004-05-12 |
2007-04-17 |
Abbott Laboratories |
Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
|
|
US7098222B2
(en)
|
2004-05-12 |
2006-08-29 |
Abbott Laboratories |
Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
|
|
US7446196B2
(en)
|
2004-06-03 |
2008-11-04 |
Kosan Biosciences, Incorporated |
Leptomycin compounds
|
|
EP1789399A1
(en)
|
2004-08-31 |
2007-05-30 |
AstraZeneca AB |
Quinazolinone derivatives and their use as b-raf inhibitors
|
|
CA2583192A1
(en)
|
2004-10-14 |
2006-04-20 |
F. Hoffmann-La Roche Ag |
1,5-naphthyridine azolidinones having cdk1 antiproliferative activity
|
|
MX2007004480A
(es)
|
2004-10-15 |
2007-05-08 |
Astrazeneca Ab |
Quinoxalinas como inhibidores b raf.
|
|
EP1659175A1
(en)
|
2004-11-18 |
2006-05-24 |
Institut Curie |
Alterations in seborrheic keratoses and their applications
|
|
CN101132781A
(zh)
|
2004-12-09 |
2008-02-27 |
茵西斯医疗公司 |
在室温下稳定的屈大麻酚剂型
|
|
CN102861019B
(zh)
|
2004-12-24 |
2016-05-25 |
诺华股份有限公司 |
治疗或预防神经性疼痛的药物
|
|
WO2006085335A2
(en)
|
2005-01-03 |
2006-08-17 |
Lupin Limited |
Pharmaceutical composition of acid labile substances
|
|
US8278290B2
(en)
|
2005-02-14 |
2012-10-02 |
Biononics Limited |
Tubulin polymerisation inhibitors
|
|
US9271963B2
(en)
|
2005-03-03 |
2016-03-01 |
Universitat Des Saarlandes |
Selective inhibitors of human corticosteroid synthases
|
|
AU2006247833A1
(en)
|
2005-05-12 |
2006-11-23 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
ATE542527T1
(de)
|
2005-05-13 |
2012-02-15 |
Topotarget Uk Ltd |
Pharmazeutische formulierungen von hdac-hemmern
|
|
BRPI0611521A2
(pt)
|
2005-05-18 |
2010-09-14 |
Wyeth Corp |
inibidores de 4,6-diamino-[1,7]naftiridina-3-carbonitrila de quìnase tpl2 e métodos de fabricação e uso dos mesmos
|
|
CA2610987C
(en)
|
2005-06-10 |
2013-09-10 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilizer for protein preparation comprising meglumine and use thereof
|
|
GB0513692D0
(en)
|
2005-07-04 |
2005-08-10 |
Karobio Ab |
Novel pharmaceutical compositions
|
|
WO2007023186A1
(en)
|
2005-08-26 |
2007-03-01 |
Laboratoires Serono S.A. |
Pyrazine derivatives and use as pi3k inhibitors
|
|
ES2513165T3
(es)
|
2005-10-07 |
2014-10-24 |
Exelixis, Inc. |
Derivados de N-(3-amino-quinoxalin-2-il)-sulfonamida y su uso como inhibidores de la fosfatidilinositol-3-quinasa
|
|
EP1790342A1
(de)
|
2005-11-11 |
2007-05-30 |
Zentaris GmbH |
Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
|
|
US8217042B2
(en)
|
2005-11-11 |
2012-07-10 |
Zentaris Gmbh |
Pyridopyrazines and their use as modulators of kinases
|
|
CA2628039A1
(en)
|
2005-11-11 |
2007-05-18 |
Aeterna Zentaris Gmbh |
Novel pyridopyrazines and their use as modulators of kinases
|
|
CN1966500B
(zh)
|
2005-11-17 |
2011-03-30 |
中国科学院上海药物研究所 |
一类喹喔啉类衍生物、制法及用途
|
|
WO2007061127A1
(ja)
|
2005-11-22 |
2007-05-31 |
Eisai R & D Management Co., Ltd. |
多発性骨髄腫に対する抗腫瘍剤
|
|
PT1966214T
(pt)
*
|
2005-12-21 |
2017-02-03 |
Janssen Pharmaceutica Nv |
Triazolpiridazinas como moduladores de tirosina quinase
|
|
AR060358A1
(es)
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
|
CA2651072A1
(en)
|
2006-05-01 |
2007-11-08 |
Pfizer Products Inc. |
Substituted 2-amino-fused heterocyclic compounds
|
|
GB0609621D0
(en)
|
2006-05-16 |
2006-06-21 |
Astrazeneca Ab |
Novel co-crystal
|
|
ATE549338T1
(de)
|
2006-05-24 |
2012-03-15 |
Boehringer Ingelheim Int |
Substituierte pteridine, die mit einem viergliedrigen heterocyclus substituiert sind
|
|
JO3235B1
(ar)
|
2006-05-26 |
2018-03-08 |
Astex Therapeutics Ltd |
مركبات بيررولوبيريميدين و استعمالاتها
|
|
WO2008003702A2
(en)
|
2006-07-03 |
2008-01-10 |
Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg |
Fused bicyclic compounds interacting with the histamine h4 receptor
|
|
JP2010500994A
(ja)
|
2006-08-16 |
2010-01-14 |
エグゼリクシス， インコーポレイテッド |
Ｐｉ３ｋおよびｍｅｋモジュレーターを使用する方法
|
|
EP2081928B1
(en)
|
2006-11-10 |
2014-02-26 |
Bristol-Myers Squibb Company |
Pyrrolo-pyridine kinase inhibitors
|
|
JP2008127446A
(ja)
|
2006-11-20 |
2008-06-05 |
Canon Inc |
１，５−ナフチリジン化合物及び有機発光素子
|
|
KR101532256B1
(ko)
|
2006-11-22 |
2015-06-29 |
인사이트 코포레이션 |
키나제 억제제로서의 이미다조트리아진 및 이미다조피리미딘
|
|
CN102123712B
(zh)
|
2006-12-13 |
2014-03-19 |
默沙东公司 |
使用igf1r抑制剂治疗癌症的方法
|
|
US7872018B2
(en)
|
2006-12-21 |
2011-01-18 |
Plexxikon, Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
|
MX2009006706A
(es)
|
2006-12-22 |
2009-07-02 |
Astex Therapeutics Ltd |
Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
|
|
AU2007336893A1
(en)
|
2006-12-22 |
2008-07-03 |
Novartis Ag |
Quinazolines for PDK1 inhibition
|
|
KR20080062876A
(ko)
|
2006-12-29 |
2008-07-03 |
주식회사 대웅제약 |
신규한 항진균성 트리아졸 유도체
|
|
WO2008109369A2
(en)
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting tnf gene expression and uses thereof
|
|
US8163923B2
(en)
|
2007-03-14 |
2012-04-24 |
Advenchen Laboratories, Llc |
Spiro substituted compounds as angiogenesis inhibitors
|
|
US7592342B2
(en)
|
2007-05-10 |
2009-09-22 |
Smithkline Beecham Corporation |
Quinoxaline derivatives as PI3 kinase inhibitors
|
|
EP1990342A1
(en)
|
2007-05-10 |
2008-11-12 |
AEterna Zentaris GmbH |
Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof
|
|
WO2008150827A1
(en)
|
2007-05-29 |
2008-12-11 |
Smithkline Beecham Corporation |
Naphthyridine, derivatives as p13 kinase inhibitors
|
|
AR066879A1
(es)
|
2007-06-08 |
2009-09-16 |
Novartis Ag |
Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
|
|
KR20130008625A
(ko)
|
2007-06-20 |
2013-01-22 |
미쓰비시 타나베 파마 코퍼레이션 |
신규한 말론산술폰아미드 유도체 및 그 의약 용도
|
|
EP2170894A1
(en)
*
|
2007-06-21 |
2010-04-07 |
Janssen Pharmaceutica N.V. |
Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1h-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline
|
|
JP2010532758A
(ja)
|
2007-07-06 |
2010-10-14 |
オーエスアイ・ファーマスーティカルズ・インコーポレーテッド |
組み合わせ抗癌療法
|
|
ES2424977T3
(es)
|
2007-08-08 |
2013-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Derivados de 2-[(2-{fenilamino}-1H-pirrolo[2,3-D]pirimidin-4-il)amino]benzamida como inhibidores de IGF-1R para el tratamiento del cáncer
|
|
WO2009021083A1
(en)
|
2007-08-09 |
2009-02-12 |
Smithkline Beecham Corporation |
Quinoxaline derivatives as pi3 kinase inhibitors
|
|
WO2009019518A1
(en)
|
2007-08-09 |
2009-02-12 |
Astrazeneca Ab |
Pyrimidine compounds having a fgfr inhibitory effect
|
|
WO2013173485A1
(en)
|
2012-05-15 |
2013-11-21 |
Predictive Biosciences, Inc. |
Detection of bladder cancers
|
|
US20090054304A1
(en)
|
2007-08-23 |
2009-02-26 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
|
ES2569528T3
(es)
|
2007-11-16 |
2016-05-11 |
Incyte Holdings Corporation |
4-pirazolil-N-arilpirimidin-2-aminas y 4-pirazolil-N-heteroarilpirimidin-2-aminas como inhibidores de quinasas Janus
|
|
DK2234600T3
(da)
|
2007-12-21 |
2014-09-08 |
Hoffmann La Roche |
Antistofformulering
|
|
US20110129456A1
(en)
|
2008-05-05 |
2011-06-02 |
Yaolin Wang |
Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
|
|
MY155535A
(en)
|
2008-05-23 |
2015-10-30 |
Novartis Ag |
Derivatives of quinolines and quinoxalines as protien tyrosine kinase inhibitors
|
|
EP2373166A4
(en)
|
2008-11-15 |
2014-11-05 |
Rib X Pharmaceuticals Inc |
ANTIMICROBIAL COMPOSITIONS
|
|
EP2356116A1
(en)
|
2008-11-20 |
2011-08-17 |
OSI Pharmaceuticals, Inc. |
Substituted pyrroloý2,3-b¨-pyridines and-pyrazines
|
|
US8716280B2
(en)
|
2009-01-21 |
2014-05-06 |
Basilea Pharmaceutica Ag |
Bicyclic antibiotics
|
|
WO2010088177A1
(en)
|
2009-02-02 |
2010-08-05 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
|
TW201041888A
(en)
|
2009-05-06 |
2010-12-01 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
|
FR2945950A1
(fr)
|
2009-05-27 |
2010-12-03 |
Elan Pharma Int Ltd |
Compositions de nanoparticules anticancereuses et procedes pour les preparer
|
|
TR201910781T4
(tr)
|
2009-06-12 |
2019-08-21 |
Abivax |
Kanser tedavisi için yararlı bileşikler.
|
|
CA2770873A1
(en)
|
2009-08-12 |
2011-02-17 |
Novartis Ag |
Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
|
|
CN102656163B
(zh)
|
2009-09-03 |
2016-01-13 |
拜奥埃内杰尼克斯公司 |
抑制pask的杂环化合物
|
|
CA2772790C
(en)
|
2009-09-04 |
2017-06-27 |
Benjamin Bader |
Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
|
|
MX336663B
(es)
|
2009-09-18 |
2016-01-27 |
Sanofi Sa |
Formulaciones en comprimido de la (4'-trifluorometilfenil)amida del acido (z)-2-ciano-3-hidroxibut-2-enoico con estabilidad mejorada.
|
|
US20110123545A1
(en)
|
2009-11-24 |
2011-05-26 |
Bristol-Myers Squibb Company |
Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases
|
|
EP2332939A1
(en)
|
2009-11-26 |
2011-06-15 |
Æterna Zentaris GmbH |
Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
|
|
EP2560966B1
(en)
|
2010-03-30 |
2021-01-06 |
Verseon International Corporation |
Multisubstituted aromatic compounds as inhibitors of thrombin
|
|
GB201007286D0
(en)
|
2010-04-30 |
2010-06-16 |
Astex Therapeutics Ltd |
New compounds
|
|
WO2011146591A1
(en)
|
2010-05-19 |
2011-11-24 |
Millennium Pharmaceuticals, Inc. |
Substituted hydroxamic acids and uses thereof
|
|
CN103153062B
(zh)
|
2010-05-24 |
2015-07-15 |
因特利凯有限责任公司 |
杂环化合物及其用途
|
|
GB201020179D0
(en)
|
2010-11-29 |
2011-01-12 |
Astex Therapeutics Ltd |
New compounds
|
|
CN102532141A
(zh)
*
|
2010-12-08 |
2012-07-04 |
中国科学院上海药物研究所 |
[1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
|
|
MX343706B
(es)
|
2011-01-31 |
2016-11-18 |
Novartis Ag |
Derivados heterocíclicos novedosos.
|
|
US20140037642A1
(en)
|
2011-02-02 |
2014-02-06 |
Amgen Inc. |
Methods and compositions relating to inhibition of igf-1r
|
|
JP6130305B2
(ja)
|
2011-02-23 |
2017-05-17 |
インテリカイン， エルエルシー |
キナーゼ阻害剤の組み合わせおよびそれらの使用
|
|
WO2012118492A1
(en)
|
2011-03-01 |
2012-09-07 |
Array Biopharma Inc. |
Heterocyclic sulfonamides as raf inhibitors
|
|
US9896730B2
(en)
|
2011-04-25 |
2018-02-20 |
OSI Pharmaceuticals, LLC |
Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
|
|
WO2013032951A1
(en)
|
2011-08-26 |
2013-03-07 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
EP3332785B1
(en)
|
2011-09-14 |
2020-05-06 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
EP2757885B1
(en)
|
2011-09-21 |
2017-03-15 |
Neupharma, Inc. |
Certain chemical entites, compositions, and methods
|
|
US20130096021A1
(en)
|
2011-09-27 |
2013-04-18 |
Arul M. Chinnaiyan |
Recurrent gene fusions in breast cancer
|
|
CN104024257A
(zh)
|
2011-10-04 |
2014-09-03 |
吉利德卡利斯托加有限责任公司 |
Pi3k的新的喹喔啉抑制剂
|
|
GB201118654D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201118652D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
BR112014009890A2
(pt)
|
2011-10-28 |
2020-10-27 |
Novartis Ag |
derivados de purina e seu uso no tratamento de doença
|
|
GB201118656D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
JO3210B1
(ar)
|
2011-10-28 |
2018-03-08 |
Merck Sharp & Dohme |
مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
|
|
GB201118675D0
(en)
|
2011-10-28 |
2011-12-14 |
Astex Therapeutics Ltd |
New compounds
|
|
AR088941A1
(es)
|
2011-11-23 |
2014-07-16 |
Bayer Ip Gmbh |
Anticuerpos anti-fgfr2 y sus usos
|
|
WO2013088191A1
(en)
|
2011-12-12 |
2013-06-20 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
|
|
US9481911B2
(en)
|
2012-03-08 |
2016-11-01 |
Astellas Pharma Inc. |
Methods for detecting FGFR3/TACC3 fusion genes
|
|
MX2014011987A
(es)
|
2012-04-03 |
2014-11-10 |
Novartis Ag |
Combinaciones de inhibidores de cinasa de tirosina y su uso.
|
|
US9254288B2
(en)
|
2012-05-07 |
2016-02-09 |
The Translational Genomics Research Institute |
Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
|
|
GB201209613D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201209609D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
|
EP2871236A4
(en)
|
2012-07-05 |
2016-03-09 |
Nat Cancer Ct |
FGFR2 fusion
|
|
EP2869816A4
(en)
|
2012-07-09 |
2016-04-20 |
Coherus Biosciences Inc |
ETANERCEPT FORMULATIONS WITH CLEAR REDUCTION OF SUBVISIBLE PARTICLES
|
|
AU2013295805B2
(en)
|
2012-07-24 |
2019-05-02 |
The Trustees Of Columbia University In The City Of New York |
Fusion proteins and methods thereof
|
|
US20150203589A1
(en)
|
2012-07-24 |
2015-07-23 |
The Trustees Of Columbia University In The City Of New York |
Fusion proteins and methods thereof
|
|
WO2014018841A1
(en)
|
2012-07-27 |
2014-01-30 |
Genentech, Inc. |
Methods of treating fgfr3 related conditions
|
|
SG11201502455TA
(en)
|
2012-09-27 |
2015-05-28 |
Chugai Pharmaceutical Co Ltd |
Fgfr3 fusion gene and pharmaceutical drug targeting same
|
|
HK1214831A1
(zh)
|
2012-11-05 |
2016-08-05 |
Foundation Medicine, Inc. |
新型融合分子及其应用
|
|
MX2015005632A
(es)
|
2012-11-07 |
2016-02-05 |
Teva Pharma |
Sales de amina de laquinimod.
|
|
US10980804B2
(en)
|
2013-01-18 |
2021-04-20 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
US9777333B2
(en)
|
2013-04-05 |
2017-10-03 |
Life Technologies Corporation |
Gene fusion
|
|
GB201307577D0
(en)
|
2013-04-26 |
2013-06-12 |
Astex Therapeutics Ltd |
New compounds
|
|
WO2014193229A2
(en)
|
2013-05-27 |
2014-12-04 |
Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis |
Novel translocations in lung cancer
|
|
JP6182262B2
(ja)
|
2013-06-14 |
2017-08-16 |
シントン・ベスローテン・フェンノートシャップ |
抗がん剤を含む安定な水溶性医薬組成物
|
|
WO2014201111A1
(en)
|
2013-06-14 |
2014-12-18 |
The Brigham And Women's Hospital, Inc. |
Treatment of mtor hyperactive related diseases and disorders
|
|
US9783853B2
(en)
|
2013-07-12 |
2017-10-10 |
The Regents Of The University Of Michigan |
Recurrent gene fusions in cancer
|
|
US10028956B2
(en)
*
|
2013-08-02 |
2018-07-24 |
Ignyta, Inc. |
Methods of treating various cancers using an AXL/cMET inhibitor in combination with other agents
|
|
US9221804B2
(en)
|
2013-10-15 |
2015-12-29 |
Janssen Pharmaceutica Nv |
Secondary alcohol quinolinyl modulators of RORγt
|
|
JO3512B1
(ar)
|
2014-03-26 |
2020-07-05 |
Astex Therapeutics Ltd |
مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
|
|
KR102479696B1
(ko)
|
2014-03-26 |
2022-12-22 |
아스텍스 테라퓨틱스 리미티드 |
Fgfr 억제제 및 igf1r 억제제의 조합물
|
|
HUE053654T2
(hu)
|
2014-03-26 |
2021-07-28 |
Astex Therapeutics Ltd |
FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
|
|
UA122564C2
(uk)
|
2014-09-26 |
2020-12-10 |
Янссен Фармацевтика Нв |
Використання панелі мутантних генів fgfr для ідентифікації пацієнтів із раковим захворюванням, які піддаються лікуванню інгібітором fgfr
|
|
JOP20200201A1
(ar)
|
2015-02-10 |
2017-06-16 |
Astex Therapeutics Ltd |
تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
|
|
MX2017010595A
(es)
|
2015-02-19 |
2018-11-12 |
Bioclin Therapeutics Inc |
Métodos, composiciones, y equipos para tratamiento de cáncer.
|
|
US10478494B2
(en)
|
2015-04-03 |
2019-11-19 |
Astex Therapeutics Ltd |
FGFR/PD-1 combination therapy for the treatment of cancer
|
|
CN105030777B
(zh)
|
2015-07-14 |
2017-07-21 |
中国人民解放军第三军医大学第三附属医院 |
增强alk‑tki疗效、延缓其耐药的复合物及其制剂
|
|
CN105147687A
(zh)
|
2015-09-28 |
2015-12-16 |
青岛华之草医药科技有限公司 |
一种治疗白血病的药物达沙替尼组合物胶囊
|
|
JOP20190280A1
(ar)
|
2017-06-02 |
2019-12-02 |
Janssen Pharmaceutica Nv |
مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
|